YOLFTbeta
Noxopharm Ltd

Noxopharm Ltd

NOX · AU · Healthcare / Biotechnology

0.037AUD+0.00 (+5.71%)

Price History

Full chart

Market Stats

Previous Close0.035
Open0.036
Day Range0.036 – 0.037
52-Week Range0.051 – 0.11
Volume875.67K
Market Cap18.13M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta0.01
50-Day Avg0.0768
200-Day Avg0.0757

About

Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. The company was incorporated in 2015 and is based in Glenhaven, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Olivier Laczka B.S., M.Sc., Ph.D.
  • Employees0
  • Headquarters60 Linksley Ave, Glenhaven, NSW, Australia, 2156, Australia
  • Websitehttps://www.noxopharm.com

Leadership

  • Dr. Olivier Laczka B.S., M.Sc., Ph.D.Chief Executive Officer
  • Mr. Shawn Pieter Van Boheemen FCPA, J.P.CFO & Company Secretary
  • Ms. Jeanette Bell Ph.D.Chief Operating Officer

Financials

Income Statement

Currency: AUD2016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue360126.30K916.53K3.75M8.28M5.61M5.43M6.01M2.40M2.82M1.43M
Growth (%)-+34983.06%+625.69%+309.22%+120.82%-32.29%-3.20%+10.71%-60.06%+17.52%-49.40%
Cost of Revenue3.35K30.26K58.88K62.10K241.44K261.72K261.51K154.53K2.94M4.27M1.74K
Gross Profit-3.35K96.04K857.65K3.69M8.04M5.35M5.17M5.86M-534.81K-1.45M-1.74K
Gross Margin-929.44%76.04%93.58%98.34%97.08%95.33%95.18%97.43%-22.28%-51.25%-0.12%
Operating Expense699.72K3.34M11.36M19.35M24.41M19.96M20.37M22.45M7.00M8.21M4.85M
Operating Income-703.07K-3.24M-10.50M-15.67M-16.37M-14.61M-15.21M-16.60M-7.54M-9.65M-4.85M
Operating Margin-195297.22%-2565.11%-1145.69%-417.69%-197.61%-260.50%-280.14%-276.12%-313.92%-342.14%-339.60%
EBITDA-699.72K-3.14M-18.93M-15.59M-4.53M-5.85M-23.70M-20.85M-5.95M-5.38M-3.40M
EBITDA Margin-194366.67%-2485.90%-2065.81%-415.76%-54.67%-104.23%-436.49%-346.85%-247.70%-190.90%-237.94%
Net Income-704.73K-3.05M-18.28M-11.22M-272.09K-9.35M-18.67M-15.06M-3.58M-4.88M-4.46M
Net Income Margin-195756.94%-2411.66%-1994.85%-299.22%-3.29%-166.66%-343.86%-250.52%-149.07%-173.15%-312.17%
R&D143.13K816.10K4.11M6.62M7.33M6.97M7.78M10.65M2.94M4.27M1.94M
R&D as % of Total Revenue39758.06%646.17%448.73%176.41%88.54%124.26%143.27%177.15%122.28%151.25%136.13%
Interest Expense011.40K238.30K667.20K3.47M2.20M77.33K40.99K31.16K503.46K1.16M
Interest Expense % of Total Revenue0.00%9.03%26.00%17.79%41.86%39.20%1.42%0.68%1.30%17.85%81.24%

Balance Sheet

Currency: AUD2016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets6.21M2.83M14.55M4.30M20.07M47.85M26.59M10.13M6.78M4.58M1.84M
Total Liabilities261.72K361.04K4.40M5.75M7.19M7.08M2.48M1.06M1.29M3.89M5.48M
Total Equity5.95M2.47M10.15M-100.67K12.87M40.78M24.12M9.07M5.50M689.96K-3.65M
Cash6.18M2.46M12.61M2.91M7.10M26.80M14.01M3.01M2.32M1.55M293.57K
Total Debt--6.56M3.93M5.00M349.31K160.62K--2.48M4.57M
Net Debt-6.18M-2.46M-9.33M1.02M-2.10M-26.45M-13.85M-3.01M-2.32M924.99K4.28M

Cash Flow

Currency: AUD2016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-549.72K-2.92M-9.08M-9.78M-11.14M-8.85M-13.73M-10.95M-684.31K-5.82M-2.71M
Investing Cash Flow-19.93K-272.69K-312.35K-3.20K337.81K225.23K123.51K123.51K02.48M-
Financing Cash Flow730.60K5.49M19.54M75.00K14.99M28.32M975.73K-178.09K02.60M1.45M
Capital Expenditure19.93K78.80K312.35K6.40K3.00K035000
Free Cash Flow-569.64K-3.00M-9.39M-9.78M-11.14M-8.85M-13.73M-10.95M-684.31K-5.82M-2.71M
Dividends Paid-0--514.53K26.80M-----
FCF to OCF103.62%102.70%103.44%100.07%100.03%100.00%100.00%100.00%100.00%100.00%100.00%
Dividend Paid to FCF-0.00%---4.62%-302.77%-----

Earnings

Report DateFeb 3, 2016Oct 3, 2016Feb 24, 2017Aug 31, 2017Feb 22, 2018Aug 30, 2018Feb 20, 2019Aug 29, 2019Feb 25, 2020Aug 31, 2020Feb 16, 2021Aug 26, 2021Feb 21, 2022Aug 25, 2022Feb 24, 2023Feb 25, 2025Sep 28, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.00---0.000.00
EPS Actual0.00-0.04-0.02-0.02-0.12-0.06-0.04-0.05-0.060.05-0.03-0.01-0.03-0.03-0.020.00-0.01
Surprise-----------------
Timing-------------After-hoursAfter-hours--

Key Statistics & Ratios

Market Cap18.13M
Enterprise Value23.64M
Trailing P/E0.00
Forward P/E0.00
Price / Sales12.70
Price / Book38.97
EPS-0.01
Book Value-0.012
Revenue (TTM)1.43M
Gross Profit (TTM)-515.65K
EBITDA-3.44M
Profit Margin0.00%
Operating Margin708.26%
Return on Equity-343.56%
Return on Assets-66.96%
Shares Outstanding307.24M
Shares Float203.47M
Beta0.01
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%